Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20238378 | 0.77 | HRH3 (0.58) | HRH3SLC6A3SIGMAR1KCNH2HTR2A | |
| SCHEMBL4932037 | 0.77 | SIGMAR1 (0.67) | HRH3SLC6A3SIGMAR1KCNH2HTR2A | |
| SCHEMBL9254022 | 0.77 | HRH3 (0.62) | HRH3SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL11648726 | 0.77 | KCNH2 (0.69) | HRH3SLC6A3SIGMAR1KCNH2HTR2A | |
| SCHEMBL11267644 | 0.76 | HRH3 (0.61) | HRH3SLC6A3SIGMAR1KCNH2HTR2A | |
| SCHEMBL791561 | 0.76 | HRH3 (0.61) | HRH3SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL8673775 | 0.76 | SIGMAR1 (0.65) | HRH3SLC6A3SIGMAR1KCNH2HTR2A | |
| SCHEMBL12073194 | 0.76 | ALDH1A1 (0.68) | HRH3SLC6A3SIGMAR1KCNH2HTR2A | |
| SCHEMBL6573503 | 0.76 | HRH3 (0.96) | HRH3SLC6A3SIGMAR1KCNH2HTR2A | |
| SCHEMBL9232873 | 0.74 | HRH3 (0.59) | HRH3SLC6A3SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107608-A1 | Ligands for use in catalytic processes | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH ETHZ (CH) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107608-A1 | Ligands for use in catalytic processes | PNKP, ITPA, PLCG2 | HRH3 2820/4885SLC6A3 2486/4885SIGMAR1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.